TickerFacts.

Exelixis, Inc. (EXEL): Cost of Revenue

Annual figures by period end, from SEC filings.

$83.70M
Year ended 2026-01-02, Fiscal 2025
$85.67M
Trailing 12 months to 2026-07-03
+13.1%
3-year compound annual growth
+18.2%
5-year compound annual growth
+35.9%
10-year compound annual growth
2011-12-31: $02012-12-31: $02013-12-31: $1.12M2014-12-31: $2.04M2016-01-01: $3.90M2016-12-30: $6.55M2017-12-29: $15.07M2018-12-28: $26.35M2020-01-03: $33.10M2021-01-01: $36.27M2021-12-31: $52.87M2022-12-30: $57.91M2023-12-29: $72.55M2025-01-03: $76.22M2026-01-02: $83.70M$83.70M
2011-12-31 Cost of Revenue (USD) 2026-01-02
Period endedCost of RevenueChange YoYSource filing
2026-01-02, Fiscal 2025$83.70M+9.8%2026-02-10, From 2025-01-04
2025-01-03, Fiscal 2024$76.22M+5.1%2026-02-10, From 2023-12-30
2023-12-29$72.55M+25.3%2026-02-10, From 2022-12-31
2022-12-30$57.91M+9.5%2025-02-11, From 2022-01-01
2021-12-31$52.87M+45.8%2024-02-06, From 2021-01-02
2021-01-01, Fiscal 2020$36.27M+9.6%2023-02-07, From 2020-01-04
2020-01-03, Fiscal 2019$33.10M+25.6%2022-02-18, From 2018-12-29
2018-12-28$26.35M+74.9%2021-02-11, From 2018-01-01
2017-12-29$15.07M+129.9%2020-02-25, From 2016-12-31
2016-12-30$6.55M+68.2%2019-02-22, From 2016-01-02
2016-01-01, Fiscal 2015$3.90M+90.7%2018-02-26, From 2015-01-03
2014-12-31$2.04M+82.7%2017-02-27, From 2014-01-01
2013-12-31$1.12Mn/a2016-02-29, From 2013-01-01
2012-12-31$0n/a2015-03-02, From 2012-01-01
2011-12-31$0n/a2014-02-20, From 2011-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Exelixis, Inc. (EXEL)2026-01-02$83.70M+9.8%
Qiagen N.V. (QGEN)2025-12-31$790.50M-21.8%
Moderna, Inc. (MRNA)2025-12-31$868.00M-40.7%
Neurocrine Biosciences Inc (NBIX)2025-12-31$52.10M+53.2%
Halozyme Therapeutics, Inc. (HALO)2025-12-31$228.77M+43.5%
Bio-Techne Corp (TECH)2026-06-30$415.97M-3.1%
Novavax Inc (NVAX)2025-12-31$73.04M-64.0%
BioCryst Pharmaceuticals Inc (BCRX)2025-12-31$19.07M+55.5%
Repligen Corp (RGEN)2025-12-31$352.01M-2.2%

Compare EXEL, QGEN, MRNA, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗